DDInter596 DDInter1658
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Doxorubicin {u} (Compound) treats {v} (Disease) stomach cancer
Doxorubicin {u} (Compound) binds {v} (Gene) AKR1A1
Doxorubicin {u} (Compound) upregulates {v} (Gene) P4HA2
Doxorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Anthracyclines
Doxorubicin {u} (Compound) downregulates {v} (Gene) TSKU
Doxorubicin {u} (Compound) causes {v} (Side Effect) Mucous membrane disorder
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) ABCC10
Doxorubicin (Compound) resembles Daunorubicin (Compound)
Doxorubicin (Compound) treats stomach cancer (Disease)
Doxorubicin (Compound) binds AKR1A1 (Gene)
Doxorubicin (Compound) upregulates P4HA2 (Gene)
Doxorubicin (Compound) is included by Anthracyclines (Pharmacologic Class)
Doxorubicin (Compound) downregulates TSKU (Gene)
Doxorubicin (Compound) causes Mucous membrane disorder (Side Effect)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene)
Doxorubicin (Compound) binds ABCC10 (Gene) and Doxorubicin (Compound) upregulates ABCC10 (Gene)